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Abstract
Background: Glycemic control and management of dyslipidemia to reduce cardiovascular risk are major
therapeutic goals in individuals with type 2 diabetes mellitus (T2DM). This study was performed to evaluate the
effects of aleglitazar, a balanced dual peroxisome proliferator-activated receptor a/g (PPARa/g) agonist, on both
lipid and glycemic parameters in obese, hypertriglyceridemic, insulin-resistant rhesus monkeys.
Methods: A 135-day efficacy study was performed in six rhesus monkeys. After a 28-day baseline assessment
(vehicle only), monkeys received oral aleglitazar 0.03 mg/kg per day for 42 days, followed by a 63-day washout
period. Plasma levels of markers of glycemic and lipid regulation were measured at baseline, at the end of the
dosing period, and at the end of the washout period.
Results: Compared with baseline values, aleglitazar 0.03 mg/kg per day reduced triglyceride levels by an average
of 89% (328 to 36 mg/dL; P = 0.0035 when normalized for baseline levels) and increased high-density lipoprotein
cholesterol levels by 125% (46 to 102 mg/dL; P = 0.0007). Furthermore, aleglitazar reduced low-density lipoprotein
cholesterol levels (41%) and increased levels of apolipoprotein A-I (17%) and A-II (17%). Aleglitazar also improved
insulin sensitivity by 60% (P = 0.001). Mean body weight was reduced by 5.9% from baseline values with aleglitazar
at this dose (P = 0.043).
Conclusions: Aleglitazar, a dual PPARa/g agonist, has beneficial effects on both lipid and glucose parameters and
may have a therapeutic role in modifying cardiovascular risk factors and improving glycemic control in patients
with T2DM.
Introduction
According to the World Health Organization, cardiovas-
cular disease accounts for half of all deaths in indivi-
duals with type 2 diabetes mellitus (T2DM) [1]. This
highlights the need to reduce the cardiovascular risk in
these individuals by management of the major T2DM-
related risk factors: dyslipidemia, hyperglycemia, hyper-
tension, and body weight [2,3]. Dyslipidemia in subjects
with T2DM is characterized by elevated levels of trigly-
cerides (TGs) and reduced levels of high-density
lipoprotein cholesterol (HDL-C). Although levels of
low-density lipoprotein cholesterol (LDL-C) are not sig-
nificantly increased, the profile in T2DM is character-
ized by atherogenic small dense particles. Statin therapy
has been proven to reduce effectively plasma levels of
LDL-C; however, effects on HDL-C and TG levels are
more modest. Therefore, a safe and efficacious therapy
that can provide improvements in the overall lipid
profile of patients with T2DM, while achieving good gly-
cemic control, would have great value in reducing the
risk of cardiovascular disease.
Research has shown that obesity-associated T2DM
that develops spontaneously under natural and “healthy”
diet conditions during adulthood in several non-human
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mulatta), closely parallels the disease affecting humans
[4-10]. Evidence from longitudinal studies has also pro-
vided thorough insight into the development of T2DM
in rhesus monkeys [6,11]. Furthermore, the profile of
naturally occurring dyslipidemia, despite a low-fat diet,
closely reflects the lipid profiles of humans [12]. As
such, these primates are a well-recognized, sponta-
neously developing animal model for the metabolic syn-
drome and T2DM in humans, and provide an excellent
preclinical screening tool for novel antidiabetic agents
[13-21].
Peroxisome proliferator-activated receptor g (PPARg)
agonists are a class of drugs that act as insulin sensiti-
zers, providing glycemic control. Agonists of the
related a-subtype of the peroxisome proliferator-
activated receptor (PPARa) improve the lipid profile,
lowering levels of TGs and raising levels of HDL-C.
An ideal dual PPARa/g agonist would provide both
glycemic control and an improved lipid profile at a
well-tolerated therapeutic dose. Aleglitazar is a new,
balanced dual PPARa/g agonist designed to optimize
glycemic and lipid benefits, and minimize PPAR-
related weight gain and edema in patients with T2DM.
In vitro binding and transactivation assays have shown
that aleglitazar is a potent and high-affinity ligand for
both PPARa (IC50 =0 . 0 0 2 8μM) and PPARg (IC50 =
0.0046 μM) [22]. The balanced affinity of aleglitazar
for both these receptors provides a dual PPARa/g ago-
nist with therapeutically desirable characteristics and
an improved safety profile [23], and distinguishes it
from previously investigated imbalanced dual PPAR
agonists that have been linked to adverse effects such
as edema and renal complications [24,25].
The aim of this study was to assess the in vivo effects
of aleglitazar on both glucose and lipid regulation in
prediabetic rhesus monkeys.
Methods
Subjects
Six adult male rhesus monkeys with metabolic syn-
drome, were included in this study, based on meeting ≥3
of the following criteria: waist circumference >40 cm or
waist/hip ratio >0.9, fasting plasma glucose >72 mg/dL,
TG >71 mg/dL, HDL-C <60 mg/dL, and blood pressure:
systolic >130 mmHg and/or diastolic >80 mmHg. This
definition parallels the criteria for the diagnosis of meta-
bolic syndrome in humans according to the Adult
Treatment Panel III guidelines [26]. The animals were
individually housed and cared for according to the
Guide for the Care and Use of Laboratory Animals [27].
Animals had ad libitum access to food (monkey chow:
Lab Diet 5047; Purina Mills, St Louis, MO, USA) and
water, and were maintained at an ambient temperature
of 20°C to 24°C with a 12-hour on-off lighting cycle.
Primates were maintained in a facility approved by the
Association for the Assessment and Accreditation of
Laboratory and Animal Care (AAALAC) and the proto-
col was approved by the Institutional Animal Care and
Use Committee.
Study design
Prior to initiation of the efficacy study, a 14-day phar-
macokinetic (PK) assessment of a single dose of aleglita-
zar at 0.1 mg/kg was carried out in the same six
animals; this consisted of vehicle administration (a piece
of fruit ~5 g) for 7 days, followed by PK assessment of a
single dose of orally administered aleglitazar (0.1 mg/kg)
(results not shown), and a 4-day washout period. The
efficacy study in the monkeys was initiated on day 15
and lasted for a total of 135 days. The efficacy study
began on day 15 with a 28-day baseline assessment
phase for all six monkeys (vehicle only). Daily dosing
with aleglitazar was started on day 44 and continued at
ad o s eo f0 . 0 3m g / k gp e rd a yf o rap e r i o do f~ 4 2d a y s
to day ~86, a 6-week dosing period. This was followed
by 63-day washout period with vehicle (fruit). A sche-
matic overview of the study design is given in Figure 1.
Following this washout period, a lower dose of aleglita-
zar (0.003 mg/kg per day) was assessed for a second
42-day period; however, as the majority of parameters
did not return to baseline during the washout period,
the results of this lower dose of aleglitazar are not
presented.
In addition to standard serum chemistry and hematolo-
gical assessments, blood samples were used to assess cir-
culating levels of glucose, hemoglobin A1c (HbA1c),
insulin, lipids, and adiponectin (a surrogate marker of
insulin sensitivity). For the high-dose efficacy study,
blood samples (2 mL each) were collected on day 2 (pre-
PK baseline), day 41 to day 43 (end of vehicle baseline),
after 23 days of dosing, and at the end of the 42-day
dosing period. Additional blood samples were collected
periodically during the washout period (14, 28, 42, 54,
and 63 days after the last dose of aleglitazar).
Figure 1 Study design. PK, pharmacokinetics.
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hyperinsulinemic clamp procedure performed immedi-
ately prior to the initiation of dosing with aleglitazar and
immediately after completion of the 42-day dosing per-
iod, with a target clamp glucose level of 85 mg/dL and a
maximum stimulated insulin level of >3000 μU/mL [4].
Electrocardiography, blood pressure, and heart rate
were assessed during the pre-PK baseline, immediately
prior to the initiation of aleglitazar, and after 42 days
of dosing. Daily food intake (24-hour biscuit count)
and biweekly body weight were recorded throughout
the study.
Assay techniques
Venous blood samples (2 mL) were drawn under light
sedation (ketamine hydrochloride 10-15 mg/kg) for
blood chemistry and hematology. Blood was collected
for serum, and also into a vacutainer tube containing
EDTA for preparation of plasma. Fasting plasma glucose
(FPG) was determined using the glucose oxidase
method. Fasting plasma insulin (IRI) was evaluated at
LINCO Diagnostic Services (St Charles, MO, USA)
using a radioimmunoassay procedure. Hematologic and
blood chemistry assays were performed by Anilab, Inc
(Millstone Township, NJ, USA), while the HbA1C level
was obtained in-house using a DCA 2000+ analyzer
(Bayer Diagnostics, Elkhart, IN, USA).
Total TG, HDL-C, LDL-C, and very low-density lipo-
protein cholesterol (VLDL-C) were assayed by Penn
Medical Laboratories (Hyattsville, MD, USA) from fresh
plasma samples that had been fractionated by ultracen-
trifugation. In addition to the TG values as part of the
basic metabolic panel, TG and lipoprotein constituents
were also determined using two additional procedures
to profile lipoprotein subclass distributions: (1) b-
quantification (Penn Medical Laboratories) and (2)
nuclear magnetic resonance (NMR) spectroscopy
(LipoScience, Raleigh, NC, USA). The NMR spectro-
scopy lipoprotein subclass profiling technique uses the
EDTA plasma from blood samples stored at -80°C
[28,29] and provides a direct measure of the concentra-
tion of a specific lipoprotein subclass.
Statistical analysis
For comparison, the baseline for the high-dose efficacy
assessment was defined as the mean of the baseline
values obtained at day 2 (prior to the PK study) and
at days 41 to 43 (prior to dosing with aleglitazar
0.03 mg/kg), and the follow-up values were defined as
the values obtained on the last day of dosing with
0.03 mg/kg aleglitazar.
Baseline and follow-up data were compared using
Student’sp a i r e dt-test. Whenever appropriate, non-
parametric tests were performed. Values are expressed
as mean ± standard error and a significance level of P =
0.05 was used throughout this study. The baseline and
follow-up data of plasma TG concentration were nor-
malized by expressing on a natural logarithmic scale in
order to compensate for the wide and non-normally dis-
tributed plasma TG concentrations.
Results
Glycemic regulation
Aleglitazar 0.03 mg/kg per day improved insulin sensi-
tivity from baseline levels, as assessed by both euglyce-
mic hyperinsulinemic clamp and adiponectin levels (a
surrogate marker of insulin sensitivity). After 42 days of
dosing, the mean glucose disposal rate (M-rate)
increased from 7.8 to 12.5 mg/kg fat-free mass (FFM)/
minute; representing a 60% increase from baseline levels
(P = 0.001; Figure 2A). Similarly, the mean levels of adi-
ponectin rose by 158% from 12.8 μg/mL at baseline to
33.0 μg/mL (P = 0.003; Figure 2B). Furthermore, circu-
lating levels of insulin declined by 58% (146 to 61.2 μU/
mL) after 42 days of dosing with aleglitazar (P = 0.042;
Figure 2C).
Aleglitazar reduced FPG levels by 15% overall (89.0 to
75.3 mg/dL; P = 0.161; Figure 2D). In the subgroup of
three monkeys with more elevated starting glucose levels
(105.8 ± 2.0 mg/dL), the glucose-lowering effect was
enhanced resulting in a 28% decline to 76.2 mg/dL.
Note that normal lean rhesus monkeys have FPG levels
of 60 to 75 mg/dL, about 20 mg/dL lower than those of
humans. FPG levels in these three hyperglycemic mon-
keys did not return to hyperglycemic levels following
the 63-day washout period. No episodes of hypoglyce-
mia were observed during treatment with aleglitazar.
Mean levels of HbA1c were non-significantly reduced
from 6.7% to 5.6% after 42 days of aleglitazar treatment
(P = 0.092), and remained low during the subsequent
washout period.
Lipid regulation
Aleglitazar decreased TG levels in all monkeys by an
average of 89% (328 to 36 mg/dL; P = 0.057) with
0.03 mg/kg per day (Figure 3A). Upon statistical
normalization of the TG levels using logarithmic
transformation, due to the wide baseline range (Figure 3A),
a highly significant decrease was observed following
administration of aleglitazar (Figure 3B; P = 0.0048).
Total HDL-C levels increased by 125% (46 to 102
mg/dL) with aleglitazar (P = 0.0007; Figure 3C). LDL-
C concentrations declined significantly by 41% with
aleglitazar (92 to 54 mg/dL; P = 0.015; Figure 4A).
Treatment with aleglitazar slightly increased the mean
levels of apolipoprotein A-I (17% increase; P = 0.096;
Figure 3D) and apolipoprotein A-II (17% increase;
P = 0.111).
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Page 3 of 8The NMR analysis of blood samples also revealed an
80% decrease in levels of the LDL2 (intermediate LDL
- 26.6 nm diameter) fraction (P = 0.019) and a non-
significant 30% increase in levels of the LDL1 (small
dense LDL - 26 nm diameter) fraction (P = 0.816) fol-
lowing administration of aleglitazar. The mean level of
the LDL3 fraction (large buoyant LDL - 27 nm
diameter) was non-significantly increased by 12% (P =
0.831). Similarly, the mean level of apolipoprotein B
dropped significantly by 57% (P = 0.035; Figure 4B)
and levels of apolipoprotein C-III were non-signifi-
cantly reduced by 36% as shown in Figure 4D (P =
0.055) for all monkeys (not normalized). Additionally,
mean VLDL-C levels decreased significantly by 93%
(P = 0.041; Figure 4C) and this decrease was seen for
all monkeys. The largest decreases in these lipid con-
stituents were seen in those monkeys with the highest
initial baseline levels.
Food intake and body weight
After 42 days of dosing with aleglitazar 0.03 mg/kg per
day, mean body weight decreased significantly by about
5.9% from baseline (P = 0.043). A significant 32%
decline in daily food intake (P = 0.0097) was observed
during administration of aleglitazar.
Safety
After 42 days of dosing with aleglitazar, mean blood
urea nitrogen (BUN)/creatinine ratios increased slightly
from a baseline value of 13.3 to 15.4 (P = 0.235). All
biochemical and hematological parameters were, and
remained, within physiologically acceptable ranges, and
no evidence of peripheral edema was observed. No
adverse events or episodes of hypoglycemia were
observed during the study.
No changes in heart rate were observed between base-
line and the end of the aleglitazar dosing period,
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Figure 2 Individual levels of A) glucose disposal rate, B) adiponectin, C) fasting plasma insulin, and D) fasting plasma glucose in
monkeys given aleglitazar 0.03 mg/kg per day. The final day of dosing at 0.03 mg/kg per day aleglitazar (labeled in the figures as day 42),
due to scheduling needs, ranged across monkeys from 44 to 46 days.
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Page 4 of 8although non-significant reductions in systolic and
diastolic blood pressure (-13%; P = 0.129 and -15%;
P = 0.187, respectively) were noted. Echocardiographic
analysis revealed a pronounced, consistent, and signifi-
cant (P = 0.0036) decrease in total peripheral resistance
(which was not compensated by a reflex tachycardia),
and a trend to increased cardiac output (P = 0.079) and
stroke volume (P = 0.227) between baseline and the end
of aleglitazar dosing. All other parameters of cardiac
function that were assessed showed no relevant changes.
These data are consistent with a mild hypotensive and
vasodilatory effect. There was no evidence of any
deleterious effect on cardiac function.
Discussion
The results of this study in prediabetic rhesus monkeys
demonstrate that the dual PPARa/g agonist aleglitazar
has marked beneficial effects on HbA1c, FPG, insulin sen-
sitivity, TGs, LDL-C, HDL-C, and other lipid parameters.
Laboratory and physiological assessments indicated that
aleglitazar was well tolerated at 0.03 mg/kg per day.
The results indicated an overall beneficial effect of ale-
glitazar on cholesterol regulation in the monkeys. With
aleglitazar, fasting TG and LDL-C levels were signifi-
cantly reduced, while HDL-C level was significantly
increased by 125%. The effects of these improvements
in the lipid profile of the monkeys are difficult to extra-
polate to disease progression, as a wide spectrum of
lipids contributes to a varying degree to the develop-
ment of cardiovascular disease or diabetes [28,30,31].
However, together with the modifications in the plasma
concentrations of all classes of apolipoprotein following
the administration of aleglitazar, as well as an apparent
change from a profile of small dense LDL to larger LDL
particles, this represents a clear shift to a less athero-
genic profile in the obese monkeys and may indicate
that progression of cardiovascular disease would be
delayed by long-term treatment with this agonist.
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Figure 3 Individual levels of a) triglyceride, b) triglyceride (normalized), c) high-density lipoprotein cholesterol, and d) apolipoprotein
A-I in monkeys given aleglitazar 0.03 mg/kg per day. The final day of dosing at 0.03 mg/kg per day aleglitazar (labeled in the figures as day
42), due to scheduling needs, ranged across monkeys from 44 to 46 days.
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Page 5 of 8In addition to the lipid benefits observed with aleglita-
zar, food intake and body weight were reduced during
administration of the study drug. A pronounced
decrease in circulating levels of TG might result from
reduced food intake, and consequently, decreased body
weight, as seen in animals treated with this dose of
aleglitazar. This differentiates aleglitazar from PPARg
agonists that are associated with increases in body
weight. The mechanism explaining these findings is not
clear, but PPARa-mediated effects of the compound on
adipose tissue (e.g., increased lipolysis and/or fatty acid
oxidation) cannot be excluded. Phase II clinical trial
data in patients with T2DM demonstrated that body
weight increased to a lesser extent with aleglitazar,
when compared with pioglitazone in a head-to-head
comparison study [32]. Although the direct comparison
between aleglitazar and pioglitazone was not performed
in our study, previous thiazolidinediones studies in
rhesus monkeys [15,33] support the notion that gains in
body weight would be less evident with aleglitazar.
Beneficial effects of aleglitazar were also evident in
improved glycemic control. Administration of aleglitazar
not only reduced FPG, fasting insulin, and HbA1c levels
in the monkeys, but also improved insulin sensitivity, as
measured by the euglycemic hyperinsulinemic clamp.
The 60% increase in glucose infusion rate following
administration of aleglitazar was in accordance with the
observed increase in plasma adiponectin, a surrogate
marker of insulin sensitivity.
The observations that aleglitazar improved glucose
and lipid regulation in a non-human primate model of
the metabolic syndrome and impaired glucose tolerance
(prediabetes), are largely consistent with previously pub-
lished studies of aleglitazar in other animal models
including Zucker Diabetic Fatty (ZDF) rats and human
ApoAI-transgenic mice [22]. The beneficial effects of
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Figure 4 Individual levels of A) low-density lipoprotein cholesterol, B) apolipoprotein B, C) very low-density lipoprotein cholesterol,
and D) apolipoprotein C-III in monkeys given aleglitazar 0.03 mg/kg per day. The final day of dosing at 0.03 mg/kg per day aleglitazar
(labeled in the figures as day 42), due to scheduling needs, ranged across monkeys from 44 to 46 days.
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Page 6 of 8aleglitazar on the lipid and glycemic profiles of the
obese monkeys in this study, especially the increase of
HDL-C levels, are consistent with other dual PPAR ago-
nists previously tested in a rhesus monkey model, such
as TAK-559 [14]. Ding et al. demonstrated that TAK-
559 treatment resulted in significant elevation of HDL-
C, increased apolipoprotein A-I, with concomitant
decreases in plasma TG and apolipoprotein B. It is
believed that enhanced reverse cholesterol transport via
HDL may be involved in the improved lipid profile in
monkeys administered dual PPAR agonists, such as ale-
glitazar and TAK-559 [34]. However, unlike aleglitazar,
TAK-559 did not elicit significant changes in the levels
of VLDL-C or LDL-C.
Selective PPARg agonists, such as thiazolidinediones,
elicit improvements in insulin sensitivity and glucose
tolerance, but are often associated with weight gain and
edema in humans [35]. Selective PPARa agonists, such
as fibrates, are associated with improvements in the
lipid profile, but are also associated with increases in
serum creatinine, with minimal effect on glycemia.
Compounds that act on both receptors may represent
an attractive treatment option, provided that the poten-
tial to improve both glycemic and lipid parameters can
be achieved within the same therapeutic window in
order to minimize the incidence of PPAR-related side
effects. In this study there were no safety concerns fol-
lowing administration of either dose of aleglitazar, with
no cases of hypoglycemia, edema, or body weight gain.
The development of previous dual PPAR agonists has
been halted by safety concerns; however, the safety pro-
file of aleglitazar is encouraging [36].
The interpretation of relevance and the extrapolation
of the results of the present study to human subjects
must be undertaken with knowledge of its limitations
that include: the subjects studied were not humans, and
dose concordance between humans and monkeys is
unknown.
Conclusions
Given the close similarity between the rhesus monkey
model used in this study and the diabetic state in
humans, these findings suggest that aleglitazar, a dual
PPARa/g agonist, has beneficial effects on both lipid
and glucose parameters and may have a therapeutic role
in modifying cardiovascular risk factors and improving
glycemic control in patients with T2DM.
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